The treatment difference between the TearCare group and LipiFlow group was 1.0 Â± 0.44 (95% CI = [0.2, 1.9], pANCOVA = 0.0201) (Figure 2A).Figure 1TearCare demonstrated significant Ocular Surface Disease Index (OSDI) score reduction compared to LipiFlow in all subjects and in subgroup with Meibomian Gland Secretion Score (MGSS) <7.